Johnson & Johnson: Attention Deficit Disorder with Hyperactivity trials

The registry lists 34 Attention Deficit Disorder with Hyperactivity studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 2Phase 2 3Phase 3 14Phase 4 10No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) ParticipantsCompletedNCT01933880Phase 4Results posted
• An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity DisorderCompletedNCT01323192Phase 3Results posted
• An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01060150Phase 4Results posted
• An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT01012622Phase 4Results posted
• Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00937040Phase 4Results posted
• CONCERTA Lab School StudyCompletedNCT00799487Phase 4Results posted
• Lab School Day Study for CONCERTA of Older Children With ADHDCompletedNCT00799409Phase 4Results posted
• Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00783835Phase 4Results posted
• The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00758160Phase 4Results posted
• A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity DisorderCompletedNCT00714688Phase 3Results posted
• Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00307684Phase 3Results posted
• A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or LisdexamfetamineCompletedNCT04132557
• A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in JapanCompletedNCT04113551
• Concerta (Methylphenidate) -To-Generic Switch StudyCompletedNCT02730572
• A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated FactorsCompletedNCT01624649
• A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity DisorderCompletedNCT01357993Phase 3
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00890292Phase 1
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00890240Phase 1
• A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00880217Phase 2
• Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity DisorderCompletedNCT00866996Phase 4
• Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult PatientsCompletedNCT00664703Phase 2
• A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.CompletedNCT00566449Phase 2
• A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity DisorderCompletedNCT00518232Phase 4
• Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)CompletedNCT00460720
• A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity DisorderCompletedNCT00326391Phase 3
• A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity DisorderCompletedNCT00326300Phase 3
• An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder ChildrenCompletedNCT00304681Phase 3
• Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269815Phase 3
• A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269802Phase 3
• A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in ChildrenCompletedNCT00269789Phase 3
• An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269776Phase 3
• An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity DisorderCompletedNCT00249353Phase 3
• A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.CompletedNCT00246220Phase 3
• CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in AdultsCompletedNCT00246207Phase 3